0000899243-15-009749.txt : 20151211 0000899243-15-009749.hdr.sgml : 20151211 20151211210032 ACCESSION NUMBER: 0000899243-15-009749 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20151210 FILED AS OF DATE: 20151211 DATE AS OF CHANGE: 20151211 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Juno Therapeutics, Inc. CENTRAL INDEX KEY: 0001594864 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 463656275 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 307 WESTLAKE AVENUE NORTH, SUITE 300 CITY: SEATTLE STATE: WA ZIP: 98109 BUSINESS PHONE: 2066960703 MAIL ADDRESS: STREET 1: 307 WESTLAKE AVENUE NORTH, SUITE 300 CITY: SEATTLE STATE: WA ZIP: 98109 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Harr Steve CENTRAL INDEX KEY: 0001627387 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36781 FILM NUMBER: 151284438 MAIL ADDRESS: STREET 1: 307 WESTLAKE AVE. NORTH, STE. 300 CITY: SEATTLE STATE: WA ZIP: 98109 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2015-12-10 0 0001594864 Juno Therapeutics, Inc. JUNO 0001627387 Harr Steve 307 WESTLAKE AVENUE NORTH, SUITE 300 SEATTLE WA 98109 0 1 0 0 See Remarks Common Stock 2015-12-10 4 S 0 31400 46.3774 D 768600 D Common Stock 2015-12-10 4 S 0 3600 46.8955 D 765000 D This transaction was executed in multiple trades at prices ranging from $45.82 to $46.81. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $46.82 to $47.08. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2014, as amended March 24, 2015. Chief Financial Officer and Head of Corporate Development /s/ Zachary Hale, attorney-in-fact 2015-12-11